MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Britain Courts Anthropic Amid US Defense Department Dispute 
Apple Turns 50: From Garage Startup to AI Crossroads 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): Pursuant to section 29 of the Danish Securities Trading Act, ALK has received notification from Jupiter Asset Management Ltd., that Jupiter Asset Management Ltd. in its capacity as investment manager for a number of clients now holds more than 5% of the share capital of ALK-Abelló A/S.
Jupiter Asset Management Ltd. now owns 5% of the company share capital equivalent to 506,562 B shares.
ALK-Abelló A/S
For further information please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
About ALK
ALK is a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. ALK is a world leader in allergy immunotherapy – a treatment of the underlying cause of allergy. The company has approximately 2,200 employees, with subsidiaries, production facilities and distributors worldwide. ALK has entered into partnership agreements with Torii, Abbott, and Seqirus to commercialise sublingual allergy immunotherapy tablets in Japan, Russia, South-East Asia, Australia and New Zealand, respectively. The company is headquartered in Hørsholm, Denmark, and listed on NASDAQ Copenhagen. Find more information at www.alk.net.
http://www.globenewswire.com/NewsRoom/AttachmentNg/ea4b2d62-c0a9-4e9e-bf69-65831455aa92
